Quantum dots based potential-resolution dual-targets electrochemiluminescent immunosensor for subtype of tumor marker and its serological evaluation.
The identification of subtypes of known tumor markers is of great importance for clinical diagnosis but still a great challenge in novel detection methodologies with simple operation and acceptable sensitivity. This work for the first time reported a quantum dots (QDs) based potential-resolved electrochemiluminescent (ECL) immunosensor to realize simultaneous detection of dual targets. Because of different surface microstructures, dimercaptosuccinic acid stabilized CdTe (DMSA-CdTe) QDs and TiO2 nanoparticles-glutathione stabilized CdTe (TiO2-GSH-CdTe) QDs composites showed a large difference of ECL peak potential (∼360 mV), which provided an access for potential-resolution detection. The ECL emission on indium tin oxide electrodes showed consistent strength during the cyclic scan, and intensity data were collected at -0.89 V and -1.25 V (vs Ag/AgCl) for DMSA-CdTe QDs and TiO2-GSH-CdTe QDs composites, respectively. The interface modification procedures of immunosensor construction were characterized by atomic force microscopy. The portion of Lens culinaris lectin affiliated isoform of alpha fetoprotein (AFP), AFP-L3%, in total AFP, is recently a novel criteria showing even higher sensitivity and specificity than AFP at the early stage of cancer. Combined with the enzyme cyclic amplification strategy, linear ranges for AFP-L3 and AFP dual-targets detection were 3.24 pg mL(-1)-32.4 ng mL(-1) and 1.0 pg mL(-1)-20 ng mL(-1), with limits of detection of 3.24 pg mL(-1) and 1.0 pg mL(-1), respectively. Compared with clinical detection data, the calculated portion of AFP-L3% by as-prepared immunosensor showed acceptable accuracy. These results open a new avenue for facile and rapid multiple-components detection based on the nano-ECL technique and provide a new clinical diagnosis platform for HCC.
Department of Clinical Laboratory, Second Affiliated Hospital of Southeast University , Nanjing 210003, People's Republic of China.
Xuan
X
Liu
State Key Laboratory of Bioelectronics, Southeast University , Nanjing 210096, People's Republic of China.
Hui
H
Jiang
Department of Clinical Laboratory, Second Affiliated Hospital of Southeast University , Nanjing 210003, People's Republic of China.
Yuan
Y
Fang
Department of Clinical Laboratory, Second Affiliated Hospital of Southeast University , Nanjing 210003, People's Republic of China.
Wei
W
Zhao
Department of Clinical Laboratory, Second Affiliated Hospital of Southeast University , Nanjing 210003, People's Republic of China.
Nianyue
N
Wang
Department of Clinical Laboratory, Second Affiliated Hospital of Southeast University , Nanjing 210003, People's Republic of China.
Guizhen
G
Zang
D055910:Antibodies, Immobilized / Q000737:chemistry / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D015374:Biosensing Techniques / Q000295:instrumentation / Q000379:methods*; D001774:Blood Chemical Analysis / Q000295:instrumentation / Q000379:methods*; D019187:Cadmium Compounds / Q000737:chemistry*; D004563:Electrochemistry; D004566:Electrodes; D005978:Glutathione / Q000737:chemistry; D006801:Humans; D007118:Immunoassay / Q000295:instrumentation / Q000379:methods*; D057230:Limit of Detection; D008163:Luminescent Measurements; D020033:Protein Isoforms / Q000097:blood; D045663:Quantum Dots / Q000737:chemistry*; D015203:Reproducibility of Results; D013691:Tellurium / Q000737:chemistry*; D014025:Titanium / Q000737:chemistry; D000509:alpha-Fetoproteins / Q000032:analysis*
D055910:Antibodies, Immobilized; D014408:Biomarkers, Tumor; D019187:Cadmium Compounds; D020033:Protein Isoforms; D000509:alpha-Fetoproteins; C009495:titanium dioxide; D014025:Titanium; D005978:Glutathione; D013691:Tellurium; C028337:cadmium telluride